Form 4: Director Nancy Lurker Executes Alkermes Equity Transactions

Director Nancy Lurker acquired and exercised equity awards in Alkermes plc, resulting in a net change in beneficial ownership.

Summary

• Director Nancy Lurker exercised 6,142 restricted stock units (RSUs) on May 21, 2026.
• 1,475 shares were withheld by the company at a price of $36.95 to satisfy tax obligations.
• The director was granted 11,538 non-qualified stock options and 5,409 RSUs on May 20, 2026.
• Following these transactions, the director holds 18,222 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity management.

Positives

• Director maintains a significant equity stake of 18,222 shares, aligning interests with shareholders.
• Equity grants indicate ongoing compensation and retention of key board leadership.

Negatives

• Tax withholding of 1,475 shares represents a minor reduction in potential total holdings.

Risks

• Future value of stock options is dependent on the company's share price performance exceeding the $36.98 exercise price.

Future Outlook

The newly granted equity awards vest on the earlier of the one-year anniversary of the grant or the next annual general meeting of shareholders.

Management Comments

• Each restricted stock unit represents a contingent right to receive one ordinary share.

Industry Context

StockSavvy.ai notes that routine equity-based compensation for directors is standard practice in the biopharmaceutical sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The use of RSUs and stock options as director compensation is consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
• Tax withholding upon RSU vesting is a standard administrative procedure.

Stakeholder Impact

• Minimal impact on shareholders as these are standard equity compensation transactions.

Next Steps

• Vesting of the 11,538 stock options and 5,409 RSUs granted on May 20, 2026.

Key Dates

Keywords

Alkermes, ALKS, Insider Trading, Form 4, Equity Compensation, Director Ownership